Cystic fibrosis gene mutations and gastrointestinal diseases

被引：9
作者：
Bahmanyar, Shahram [1 ,2 ]
Ekbom, Anders
Askling, Johan
Johannesson, Marie [3 ]
Montgomery, Scott M. [4 ,5 ]
机构：
[1] Karolinska Inst, Karolinska Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden
[2] Golestan Univ Med Sci, Fac Med, Gorgan, Iran
[3] Univ Otago, Dept Paediat & Child Hlth, Wellington, New Zealand
[4] Orebro Univ Hosp, Clin Epidemiol & Biostat Unit, Orebro, Sweden
[5] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Primary Care & Social Med, London, England
来源：
JOURNAL OF CYSTIC FIBROSIS | 2010年 / 9卷 / 04期
基金：
瑞典研究理事会;
关键词：
Cystic fibrosis; Gene mutation; Gastrointestinal diseases; Barrier function; CFTR MUTATIONS; RISK;
D O I：
10.1016/j.jcf.2010.03.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Background: This study examined if CF mutation heterozygosity is associated with diseases of gastrointestinal epithelial barrier function. Design and methods: Swedish registers identified 865 patients with a diagnosis of CF between 1968 and 2003 and matched with 8101 individuals without CF. Gastrointestinal disease risk was examined among 1534 biological parents and 1396 siblings of CF patients, compared with 15,526 parents and 15,542 siblings of individuals without CF. Results: First-degree relatives of CF patients were not at lower risk of the gastrointestinal diseases, in contrast with a raised risk among CF patients. Conclusion: Heterozygosity for CF gene mutations does not protect against gastrointestinal diseases where impaired barrier function may be relevant. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：288 / 291
页数：4
相关论文
共 17 条
[1]   Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening [J].
Bobadilla, JL ;
Macek, M ;
Fine, JP ;
Farrell, PM .
HUMAN MUTATION, 2002, 19 (06) :575-606
[2]   A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes [J].
Castellani, C ;
Quinzii, C ;
Altieri, S ;
Mastella, G ;
Assael, BM .
GENETIC TESTING, 2001, 5 (03) :249-254
[3]   CYSTIC-FIBROSIS HETEROZYGOTE RESISTANCE TO CHOLERA-TOXIN IN THE CYSTIC-FIBROSIS MOUSE MODEL [J].
GABRIEL, SE ;
BRIGMAN, KN ;
KOLLER, BH ;
BOUCHER, RC ;
STUTTS, MJ .
SCIENCE, 1994, 266 (5182) :107-109
[4]   Active intestinal chloride secretion in human carriers of cystic fibrosis mutations:: An evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion [J].
Högenauer, C ;
Santa Ana, CA ;
Porter, JL ;
Millard, M ;
Gelfand, A ;
Rosenblatt, RL ;
Prestidge, CB ;
Fordtran, JS .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (06) :1422-1427
[5]   Role of Helicobacter pylori infection and non-steroidal antiinflammatory drugs in peptic-ulcer disease:: a meta-analysis [J].
Huang, JQ ;
Sridhar, S ;
Hunt, RH .
LANCET, 2002, 359 (9300) :14-22
[6]   Cancer risk among patients with cystic fibrosis and their first-degree relatives [J].
Johannesson, Marie ;
Askling, Johan ;
Montgomery, Scott M. ;
Ekbom, Anders ;
Bahmanyar, Shahram .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (12) :2953-2956
[7]   Demographic transition of the Swedish cystic fibrosis community - results of modern care [J].
Lannefors, L ;
Lindgren, A .
RESPIRATORY MEDICINE, 2002, 96 (09) :681-685
[8]   CROHNS-DISEASE AND CYSTIC-FIBROSIS [J].
LLOYDSTILL, JD .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (04) :880-885
[9]   The Gut Microbiota in Inflammatory Bowel Disease [J].
Macfarlane, G. T. ;
Blackett, K. L. ;
Nakayama, T. ;
Steed, H. ;
Macfarlane, S. .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (13) :1528-1536
[10]  
MCCARTHY VP, 1984, GASTROENTEROLOGY, V86, P564
12